ANN ARBOR – William Brinkerhoff has joined the Board of Directors at Velcura Therapeutics. Brinkerhoff was vice president of
business development for Esperion Therapeutics in Ann Arbor, where he
successfully negotiated multiple large potential partnering agreements
prior to Esperion’s acquisition by Pfizer for $1.3 billion.
Velcura just completed a first-in-man clinical trial for VEL-0230, an anti-inflammatory agent stimulating bone formation and inhibiting bone loss. Velcura is investigating its lead compound as a treatment for rheumatoid arthritis and other bone diseases.
Brinkerhoff is the chief operating officer of Cerenis
Therapeutics, which is focused on the discovery, development and
commercialization of breakthrough HDL-related therapies for the treatment
of cardiovascular and metabolic diseases.
“In joining Velcura’s Board, I look forward to assisting them in their
mission of developing therapies that restore bone health,” Brinkerhoff said.
Before joining Esperion in 2002,
Brinkerhoff was the director of business development and director of market planning and sales operations, for Sankyo Parke Davis in Parsippany, New Jersey.
A graduate of the University of Michigan, Brinkerhoff earned his Master
of Business Administration with Distinction in 1989. He also has bachelor’s
and master’s degrees in Industrial Engineering and Operations Research from
U-M’s College of Engineering.
Velcura’s other directors are CEO Michael Long and Bill Orobone, CEO of
Syneptics, an alternative energy financing entity.
More information, click on Velcura.Com
a>>
